- Jupiter Wellness Inc JUPW Has signed an exclusive license agreement With joy inc to develop prescription products for the treatment of nipple neuropathies for breast cancer patients.
- The exclusive license covers granted patents and technology, including formulations.
- Related: Jupiter Wellness Sees Sales Jump 400% in Second Quarter
- In clinical studies, a topical formulation improved nipple sensitivity and alleviated associated sexual problems.
- The product is called JW-500 and is intended to be added to a number of other clinical-stage products currently in development.
- Jupiter Wellness plans to submit an application for a pre-IND meeting to the FDA within the next 12 months and intends to apply for orphan drug designation.
- Price promotion: JUPW shares are trading up 1.63% at $1.05 on the latest check Tuesday.
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
